Some clinically important antibiotics | |||
Antibiotic
|
Producer
organism
|
Activity
|
Site
or mode of action
|
Penicillin
|
Penicillium chrysogenum
|
Gram-positive bacteria
|
Wall synthesis
|
Cephalosporin | Cephalosporium acremonium | Broad spectrum | Wall synthesis |
Griseofulvin | Penicillium griseofulvum | Dermatophytic fungi | Microtubules |
Bacitracin | Bacillus subtilis | Gram-positive bacteria | Wall synthesis |
Polymyxin B | Bacillus polymyxa | Gram-negative bacteria | Cell membrane |
Amphotericin B | Streptomyces nodosus | Fungi | Cell membrane |
Erythromycin | Streptomyces erythreus | Gram-positive bacteria | Protein synthesis |
Neomycin | Streptomyces fradiae | Broad spectrum | Protein synthesis |
Streptomycin | Streptomyces griseus | Gram-negative bacteria | Protein synthesis |
Tetracycline | Streptomyces rimosus | Broad spectrum | Protein synthesis |
Vancomycin | Streptomyces orientalis | Gram-positive bacteria | Protein synthesis |
Gentamicin | Micromonospora purpurea | Broad spectrum | Protein synthesis |
Rifamycin | Streptomyces mediterranei | Tuberculosis | Protein synthesis |
Antibiotics are the new "old frontier " for target therapy for cancer treatment
and I am not talking of cell wall agents, but agents that target miRNA. Griseofulvin targets Microtubules but there is a different in nature of microtubules that makes it ineffective for human. It may need some tweaking. Anti ribosomal drugs (80s) may also be of interest.
Go ahead and look into these
1. Polymyxin
2. Rifamycin
3. Avenacin
4. Cinnamic Acid
5. Phtalic Acid
6. Suramin ie.
----------------------
NCI
" Suramin
A polysulphonated naphthylurea with potential antineoplastic
activity. Suramin blocks the binding of various growth factors,
including insulin-like growth factor I (IGF-I), epidermal growth factor
(EGF), platelet-derived growth factor (PDGF), and tumor growth
factor-beta (TGF-beta), to their receptors, thereby inhibiting
endothelial cell proliferation and migration. This agent also inhibits
vascular endothelial growth factor (VEGF)- and basic fibroblast growth
factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase;
uncoupling of G-proteins from receptors; topoisomerases; cellular folate
transport; and steroidogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)'"